In‐host modeling of dengue virus and non‐structural protein 1 and the effects of ivermectin in patients with acute dengue fever
CPT: Pharmacometrics & Systems Pharmacology · 2024
DOI: 10.1002/psp4.13233 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Junjie Ding und 15 weiteren Autor:innen. Beteiligte Einrichtung: Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Ivermectin, Viral Nonstructural Proteins, Dengue, Dengue Virus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Faculty of Medicine Siriraj Hospital, Higher Education Commission, Department of Disease Control, Ministry of Public Health.
Abstract (Originalsprache)
The increased incidence of dengue poses a substantially global public health challenge. There are no approved antiviral drugs to treat dengue infections. Ivermectin, an old anti‐parasitic drug, had no effect on dengue viremia, but reduced the dengue non‐structural protein 1 (NS1) in a clinical trial. This is potentially important, as NS1 may play a causal role in the pathogenesis of severe dengue. This study established an in‐host model to characterize the plasma kinetics of dengue virus and NS1 with host immunity and evaluated the effects of ivermectin, using a population pharmacokinetic–pharmacodynamic (PK–PD) modeling approach, based on two studies in acute dengue fever: a placebo‐controlled ivermectin study in 250 adult patients and an ivermectin PK–PD study in 24 pediatric patients. The proposed model described adequately the observed ivermectin pharmacokinetics, viral load, and NS1 data. Bodyweight was a significant covariate on ivermectin pharmacokinetics. We found that ivermectin reduced NS1 with an EC 50 of 67.5 μg/mL. In silico simulations suggested that ivermectin should be dosed within 48 h after fever onset, and that a daily dosage of 800 μg/kg could achieve substantial NS1 reduction. The in‐host dengue model is useful to assess the drug effect in antiviral drug development for dengue fever.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
- Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
- Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani, Thailand.
- Division of Dengue Hemorrhagic Fever Research, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Junjie Ding, Dumrong Mairiang, Chunya Puttikhunt, Sansanee Noisakran, Adisak Songjaeng, Tanapan Prommool, Nasikarn Angkasekwinai, Yupin Suputtamongkol, Keswadee Lapphra, Kulkanya Chokephaibulkit, Nicholas J White, Panisadee Avirutnan, Joel Tarning
Förderung
- Faculty of Medicine Siriraj Hospital
- Higher Education Commission
- Department of Disease Control, Ministry of Public Health
- Wellcome Trust
- Health Systems Research Institute
- Mahidol University under the National Research Universities Initiative, Thailand Research Fund
- Higher Education Commission Mauritius
Zitieren
APA
Ding, J., Mairiang, D., Prayongkul, D., Puttikhunt, C., Noisakran, S., Kaewjiw, N., Songjaeng, A., Prommool, T., Tangthawornchaikul, N., Angkasekwinai, N., Suputtamongkol, Y., Lapphra, K., Chokephaibulkit, K., White, N. J., Avirutnan, P., & Tarning, J. (2024). In‐host modeling of dengue virus and non‐structural protein 1 and the effects of ivermectin in patients with acute dengue fever. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13233
Vancouver
Ding J, Mairiang D, Prayongkul D, Puttikhunt C, Noisakran S, Kaewjiw N, et al. In‐host modeling of dengue virus and non‐structural protein 1 and the effects of ivermectin in patients with acute dengue fever. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13233
BibTeX
@article{Ding2024,
author = {Ding, Junjie and Mairiang, Dumrong and Prayongkul, Dararat and Puttikhunt, Chunya and Noisakran, Sansanee and Kaewjiw, Nattapong and Songjaeng, Adisak and Prommool, Tanapan and Tangthawornchaikul, Nattaya and Angkasekwinai, Nasikarn and Suputtamongkol, Yupin and Lapphra, Keswadee and Chokephaibulkit, Kulkanya and White, Nicholas J and Avirutnan, Panisadee and Tarning, Joel},
title = {In‐host modeling of dengue virus and non‐structural protein 1 and the effects of ivermectin in patients with acute dengue fever},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
doi = {10.1002/psp4.13233}
}
EUVIMED